Open AccessExtreme Thrombocytosis in Refractory ITP Post-Splenectomy With Associated Fatal Thromboembolism
Author(s) -
Rithin Nedumannil,
Emma Leitinger,
Surender Juneja
Publication year - 2022
Publication title -
clinical pathology
Language(s) - English
Resource type - Journals
ISSN - 2632-010X
DOI - 10.1177/2632010x221083218
Subject(s) - thrombocytosis , thrombopoietin , refractory (planetary science) , medicine , splenectomy , immune thrombocytopenia , thrombopoietin receptor , myeloproliferative neoplasm , agonist , platelet , romiplostim , gastroenterology , immunology , myelofibrosis , receptor , spleen , haematopoiesis , biology , bone marrow , stem cell , astrobiology , genetics
Thrombopoietin (TPO)-receptor agonists have heralded a paradigm shift in the treatment of refractory immune thrombocytopenia (ITP). Reactive thrombocytosis has been described as a secondary effect of such therapies. However, the phenomenon of extreme thrombocytosis with morphology mimicking a myeloproliferative neoplasm (MPN) followed by fatal thromboembolism is unusual in this setting. Caution is required in the diagnosis of refractory ITP as well as TPO-receptor agonist dosing in such cases.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom